How Research Peptides Are Tested

Preclinical research begins in test tubes and cells, where researchers characterise the peptide's binding to target receptors, its effects on cell signalling, and basic toxicity. Animal models (mice, rats, dogs) follow, assessing pharmacokinetics (absorption, distribution, metabolism, excretion), pharmacodynamics (dose-response relationship), and safety in living organisms.

Preclinical data helps identify promising peptides and predicts potential human safety issues.

Phase 1 trials involve small groups (20–100 people) of healthy volunteers or affected patients, assessing safety, tolerability, and pharmacokinetics at escalating doses. Phase 2 trials involve larger groups (100–500 people) with the target condition, evaluating preliminary efficacy and continuing safety monitoring.

If these phases are successful, the peptide progresses to Phase 3.

Phase 3 involves larger populations (500–5000 people), comparing the peptide to placebo or standard treatment. These well-designed, often multi-site trials generate the primary evidence of efficacy and safety for regulatory approval.

Regulatory agencies base approval decisions primarily on Phase 3 data.

After approval, Phase 4 surveillance continues to monitor safety in large, diverse populations. Healthcare providers and patients report adverse events. Rare adverse effects not apparent in trials may emerge at population scale.

Most peptides discussed online are research peptides—compounds that have not progressed through this full pipeline. They may be at any stage: early preclinical, early clinical, or stalled at an earlier phase. This is why research peptide evidence is typically preliminary and safety is incompletely characterised.